Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Phase 1

Completed

• Conditions: Acute Coronary Syndrome; Ischemic Stroke
• Interventions: Drug: Tiprogrel; Drug: Clopidogrel; Drug: Ticagrelor

• Registration Number: NCT06584812
• Lead Sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd

Brief Summary

This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.

Detailed Description

Tiprogrel is a novel oral P2Y12 receptor antagonist.This study is to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel, and compare pharmacokinetics /pharmacodynamic of Tiprogrel,Clopidogrel and Ticagrelor.

Study Timeline

• Study First Submitted: 2024-08-29
• Study First Submitted QC: 2024-09-02
• Study First Posted: 2024-09-05
• Study Start: 2024-09-09
• Primary Completion: 2024-12-05
• Study Completion: 2024-12-17
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-02
• Last Update Posted: 2025-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Male and female Healthy Subjects
2. Subject has the ability and willingness to comply with study procedures and follow-up examination.

3：18 to 50 years of age (including the threshold) 4: Body mass index (BMI) ≥ 19.0 to ≤ 28.0 kg/m2; total body weight of male subject ≥ 50 kg at Screening; total body weight of female subject ≥ 45 kg at Screening; 5：Medically healthy based on their medical history, and physical examination, clinical laboratory test results, ECGs, and vital sign measurements as determined by the Investigator at Screening; 6: Female subjects are not pregnant or breastfeeding, and the fertile female and male subjects must agree to follow instructions for method(s) of contraception.

Exclusion Criteria

1. History or presence of metabolic, allergy, dermatology, liver, kidney, hematology, cardiovascular, gastrointestinal, nervous, respiratory, endocrine or psychiatric diseases.
2. History or presence of obviously active bleeding, or coagulation or bleeding disorders, or any skin petechiae, or thrombus, or spontaneous bleeding.
3. Subject with history of allergy to a variety of drugs, or has a known or suspected hypersensitivity to tiprogrel or other anti-platelet drugs
4. Subjects who had a history of major surgery within 3 months before the trial or planned to undergo surgery during the study period.
5. Subjects who have lost or donated ≥ 400 mL blood or received blood transfusion or used blood products within three months, or subjects with clinically significant anemia based on the judgment of the Investigator
6. Subjects with systolic blood pressure of > 140 mmHg or < 90 mmHg, diastolic blood pressure of > 90 mmHg or < 60 mmHg
7. Subjects with 12-lead ECG examination: QTcF > 450 msec
8. Platelet count (PLT) value, beyond the laboratory's reference range
9. Activated partial thromboplastin time (APTT) and Prothrombin Time (PT), beyond the laboratory's reference range
10. ALT, AST, γ-GGT, ALP and TBIL value >1.5 times the upper limit of normal value
11. Subjects with positive results at screening for HIV, syphilis, HBsAg, or HCV
12. Subjects who have taken aspirin/other nonsteroidal anti-inflammatory drugs (NSAIDs) or other drugs that may affect coagulation function within 2 weeks before the trial
13. Subjects who have taken prescription drugs/products or herbs within 2 weeks or 5 half-lives (whichever is longer) before the trial;or taken OTC drugs/products within 7 days before the trial.
14. Subjects who have received live or attenuated vaccines within 1 month prior to receiving the study drug or expected to receive vaccines during the study period
15. Subjects who have ingested investigational drug within 3 months or 5 half-lives prior to the first study drug dose
16. Subjects who have participated in another clinical trial within 3 months or 5 half-lives prior to the first study drug dose;
17. Consumption of any known liver enzyme inducers/inhibitors within 30 days prior to the first study drug dose;
18. Have a history of drug addiction or drug abuse within 1 year prior to screening;
19. Positive results for alcohol, or cotinine, or urine for drugs test in screening or admission;
20. Subject with alcohol consumption defined as > 21 units per week for men and > 14 units per week for woman;
21. Use of tobacco or nicotine-containing products within 1 month prior to screening;
22. CYP2C19 poor metabolizer;
23. Subjects with a history of fainting needle or blood;
24. Subjects who are not suitable to participate in this experiment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Tiprogrel-Clopidogrel-Ticagrelor	Tiprogrel	Period 1: Dose 1 Tiprogrel; Period 2: Dose 2 Tiprogrel ; Period 3: Clopidogrel; Period 4: Ticagrelor
Tiprogrel-Clopidogrel-Ticagrelor	Clopidogrel	Period 1: Dose 1 Tiprogrel; Period 2: Dose 2 Tiprogrel ; Period 3: Clopidogrel; Period 4: Ticagrelor
Tiprogrel-Clopidogrel-Ticagrelor	Ticagrelor	Period 1: Dose 1 Tiprogrel; Period 2: Dose 2 Tiprogrel ; Period 3: Clopidogrel; Period 4: Ticagrelor

Primary Outcome Measures

Name	Time	Method
PK parameters： Cmax	Day 1 to Day 9 in each period	Maximum Concentration of Clopidogrel 's active metabolite
PK parameters： AUC	Day 1 to Day 9 in each period	Area under the plasma concentration curve of Clopidogrel 's active metabolite
PK parameters： Tmax	Day 1 to Day 9 in each period	Time to maximum concentration of Clopidogrel 's active metabolite
PK parameters： T1/2	Day 1 to Day 9 in each period	Half life of Clopidogrel 's active metabolite
PD parameters: Adenosine Diphosphate(ADP)-induced P2Y12 Receptor-mediated platelet aggregation of Tiprogrel	Day 1 to Day 14 in each period	ADP-induced platelet reaction unit represents the rate and extent of ADP-stimulated platelet aggregation
PD parameters: Adenosine Diphosphate(ADP)-induced P2Y12 Receptor-mediated platelet aggregation of Clopidogrel	Day 1 to Day 14 in each period	ADP-induced platelet reaction unit represents the rate and extent of ADP-stimulated platelet aggregation
PD parameters: Adenosine Diphosphate(ADP)-induced P2Y12 Receptor-mediated platelet aggregation of Ticagrelor	Day 1 to Day 14 in each period	ADP-induced platelet reaction unit represents the rate and extent of ADP-stimulated platelet aggregation
Safety parameters: Number of Participants With Treatment-Related Adverse Events	Day 1 to Day 14 in each period

Trial Locations

Locations (1)

Beijing Tiantan Hosptial, Capital Medical University; 🇨🇳 Beijing, China